金沙娱城乐377

金沙娱城乐377

中文

公司新闻

当前位置: 首页 > 新闻动态 > 公司新闻

金沙医疗新靶点抗肿瘤药物LH031一期临床研究首例受试者入组给药!

2019-05-31

 

    5月31日,金沙娱城总站3777医疗的抗肿瘤新药LH031的I期临床试验顺利完成首例受试者入组给药。口服LH031拟在血液肿瘤以及实体肿瘤等几个意向性适应症上进行剂量以及安全性的探索。LH031为全球首个口服给药的EG5抑制剂,在临床前模型上表现出显著的肿瘤抑制作用,而口服给药具有注射EG5抑制剂无法比拟的优势以及明显的靶向优势。 LH031目前拟开发的适应症包括多发性骨髓瘤,乳腺癌,脑胶质瘤等等。该研究计划在广州中山大学肿瘤防治中心完成。


      May 31, Link Health Group successfully complete the first dosing for the first patient in PI study of LH031. LH031 is an innovative drug shows significant anti-cancer efficacy on animal models based on its inhibition of EG5. LH031 is the fist and also the best-in-class EG5 inhibitor to be planned to test on several cancers like MM, Breast cancer, GBM, etc. Several previous studies have been done and published before on those indications. The studies include dosage escalation and safety evaluation, which will be done in Sun Yat-sen University Cancer Center in Guangzhou.